9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
36 hedge funds and large institutions have $46.7M invested in 9 Meters Biopharma in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 6 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
452% more call options, than puts
Call options by funds: $1.85M | Put options by funds: $335K
350% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 6
140% more funds holding
Funds holding: 15 → 36 (+21)
92% more capital invested
Capital invested by funds: $24.3M → $46.7M (+$22.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$16.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.74M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.22M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.02M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$927K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$3.52M |
| 2 |
Millennium Management
New York
|
-$2.09M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.3M |
| 4 |
ECM
Element Capital Management
New York
|
-$580K |
| 5 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$315K |
NMTR Hedge Fund Activity: Q2 2018 in Review
36 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q2 2018, worth a combined $46.7M — up 92% from $24.3M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new NMTR positions and 6 closed out — a net gain of 21 holders — while 6 added to existing stakes and 1 trimmed.
The largest buyer was BlackRock, adding an estimated $16.2M. The largest seller was Goldman Sachs, exiting entirely with an estimated $3.52M sold.
- 36 institutional investors held 9 Meters Biopharma (NMTR) as of Q2 2018, up from 15 in Q1 2018.
- Funds reported $46.7M of 9 Meters Biopharma stock for Q2 2018, up 92% quarter-over-quarter.
- 27 funds opened new 9 Meters Biopharma positions in Q2 2018 and 6 closed out, a net change of +21 holders.
- The largest 9 Meters Biopharma buyer in Q2 2018 was BlackRock, an estimated $16.2M added.
- The largest 9 Meters Biopharma seller in Q2 2018 was Goldman Sachs, an estimated $3.52M sold.
Based on aggregated 13F filings for Q2 2018.